Mr. Nancyzhu
Address:
No. 16 Dalian Road, Baohe Industrial Park, Hefei, Anhui, China
Telephone:
Zip Code:
Fax:
| Please sign in to view contact details |
Account Registered in:
2019
Business Range:
Health & Medicine
Management System Certification:
GMP
Business Type:
Manufacturer/Factory
Company Introduction
Production Capacity
BBCA Pharmaceuticals is located in the capital of Anhui province, Hefei. It is the largest pharmaceutical enterprise in Anhui. It is the high technology enterprise determined by The Ministry of Science and Technology and Chinese Academy of Sciences, as well as the national GMP certified enterprise and the -People-trusted drug brand- awarded by Chinese government in 2006. It was listed in Sep 4, ...
BBCA Pharmaceuticals is located in the capital of Anhui province, Hefei. It is the largest pharmaceutical enterprise in Anhui. It is the high technology enterprise determined by The Ministry of Science and Technology and Chinese Academy of Sciences, as well as the national GMP certified enterprise and the -People-trusted drug brand- awarded by Chinese government in 2006. It was listed in Sep 4, 2000 in Shenzhen
Stock Exchange after obtaining the approval of China Securities
Regulatory Commission. Up to the end of 2008, the company had more than 4500 employees and a total capital of about 1.5 billion RMB. BBCA Pharmaceuticals is constituted of three systems which are pharmaceutical R&D, production, and sale. It has 7 pharmaceutical plants and 45 GMP certified production line, mainly involving R&D, production and sale of
Biological pharmacy, chemical pharmacy, and traditional Chinese medicine, and possessing nine classes of products including antipyretic-analgesic drug, cardiovascular drug, antibiotic, nervous system drug, anti-tumor drug, antiulcer drug, hormones drug, nutriceutical, and preparation of traditional Chinese medicine, etc.
BBCA Pharmaceuticals can produce 11 kinds of dosage form, including large-volume injection, small-volume injection, powder injection, capsules, powders, tablets, granules, films, eye drops, patches, etc, 395 varieties, as well as many kinds of material drugs. There are more than 40 varieties of national new drugs being researched and developed, some of which have come into the market. BBCA Pharmaceuticals has many varieties of the first and second national new medicine and has the independent intellectual property of the products and various production technologies. While pursuing scale and series production, the company carried out the strategy of omnidirectional market cultivation and development, based on Anhui and influencing the world. It has set up the sales offices in more than 30 provinces, municipalities and autonomous regions all over the country. The sales networks for some products have been established in Southeast Asia, Africa, and South America.
Stock Exchange after obtaining the approval of China Securities
Regulatory Commission. Up to the end of 2008, the company had more than 4500 employees and a total capital of about 1.5 billion RMB. BBCA Pharmaceuticals is constituted of three systems which are pharmaceutical R&D, production, and sale. It has 7 pharmaceutical plants and 45 GMP certified production line, mainly involving R&D, production and sale of
Biological pharmacy, chemical pharmacy, and traditional Chinese medicine, and possessing nine classes of products including antipyretic-analgesic drug, cardiovascular drug, antibiotic, nervous system drug, anti-tumor drug, antiulcer drug, hormones drug, nutriceutical, and preparation of traditional Chinese medicine, etc.
BBCA Pharmaceuticals can produce 11 kinds of dosage form, including large-volume injection, small-volume injection, powder injection, capsules, powders, tablets, granules, films, eye drops, patches, etc, 395 varieties, as well as many kinds of material drugs. There are more than 40 varieties of national new drugs being researched and developed, some of which have come into the market. BBCA Pharmaceuticals has many varieties of the first and second national new medicine and has the independent intellectual property of the products and various production technologies. While pursuing scale and series production, the company carried out the strategy of omnidirectional market cultivation and development, based on Anhui and influencing the world. It has set up the sales offices in more than 30 provinces, municipalities and autonomous regions all over the country. The sales networks for some products have been established in Southeast Asia, Africa, and South America.
Factory Address:
No. 16 Dalian Road, Baohe Industrial Park, Hefei, Anhui, China
R&D Capacity:
Own Brand()
No. of R&D Staff:
Above 50 People
No. of Production Lines:
Above 10
